

# Pharmacy BULLETIN BOARD

Industry Issue ■ Monday February 24, 2014.

**UriSec®** emollient creams and lotion are patient friendly formulations ideal for winter dryness and itchy skin.

Product	NPN	Sizes	Odan Code	UPC
UriSec® 10% Cream	80005397	75 g	38075	776097380751
		120 g	38045	776097380454
UriSec 12% Lotion	00514896	250 mL	230J	776097230254
UriSec® 22% Cream	00396125	120 g	220Q	776097220453
		225 g	220C	776097220651
		454 g	220R	776097220859
UriSec® 40 Cream	80005531	15 g	45014	776097450140
		30 g	45028	776097450287
		100 g	45067	776097450676

**UriSec®** products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com). You can also visit our website at [www.odanlab.com](http://www.odanlab.com).



UriSec® is a registered trademark of Odan Laboratories Ltd.

## ■ FROM THE NEWSWIRE ■

**OTTAWA:** In light of the growing employment challenges facing Canadian doctors and the impact on patient care, the Steering Committee of the National Physician Employment Summit is calling for action to help highly-trained doctors work to their capacity to meet the needs of the public.

**LUND, Sweden:** BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced the launch of a new registry to collect long term data of CERAMENT™|G, the first injectable antibiotic eluting, osteoconductive, ceramic bone substitute indicated to promote and protect bone healing being jeopardized by infection. The registry is part of the company's Centers of Excellence expansion plan and aims to advance research, discovery and the development of improved treatment protocols for osteomyelitis.

**MONTREAL:** Every year, the Cancer Research Society receives several applications from researchers across Canada, as part of its annual operating grant competition. In 2013, thanks to the generosity of thousands of donors, the Cancer Research Society was able to award its highest amount ever of \$11.5 million, to more than 50 exciting new research initiatives which brings to 120 the number of projects currently underway and financed by the Society. Through a combination of monthly and one-time donations, planned gifts, fundraisers, events and partnerships, Canadians showed their unwavering support for cancer research, with tangible results: giving some of the country's best researchers the means to get their important work off the ground.

**MISSISSAUGA:** Biogen Idec Canada announced the Health Canada approval of TECFIDERA™ (dimethyl fumarate) 240 mg strength capsule, a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA™ was first approved by Health Canada in April 2013 as a 120 mg capsule indicated as monotherapy for the treatment of relapsing-remitting MS to reduce the frequency of clinical exacerbations and to delay the progression of disability.

**To include your communication in the next issue, please contact: Health Response**

T: 416-863-5403 | F: 416-863-9620 | [hrc@healthresponse.ca](mailto:hrc@healthresponse.ca)

**Next Issue: Monday March 10<sup>th</sup>, 2014**

Deadline: Thursday March 6<sup>th</sup>, 2014